CVRx, Inc. (CVRX)
After hours:
| Previous close | 14.39 |
| Open | 14.43 |
| Bid | 14.65 x 100 |
| Ask | 14.73 x 100 |
| Day's range | 14.23 - 14.85 |
| 52-week range | 9.92 - 33.13 |
| Volume | |
| Avg. volume | 131,598 |
| Market cap | 317.238M |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings date | 23 July 2024 - 29 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 32.50 |
ZacksCVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits
CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.
GlobeNewswireCVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release first quarter 2024 financial and operating results after market close on Tuesday, April 30th, 2024. The Company will host a conference call to review its resul
- GlobeNewswire
CVRx announces availability of additional data supporting long-term benefits of Barostim
BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., April 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of Heart Failure. These data highlight long-term sustained benefits of Barostim in heart f
